Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor

@article{Palmer1987NitricOR,
  title={Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor},
  author={R. M. Palmer and A. Ferrige and S. Moncada},
  journal={Nature},
  year={1987},
  volume={327},
  pages={524-526}
}
  • R. M. Palmer, A. Ferrige, S. Moncada
  • Published 1987
  • Chemistry, Medicine
  • Nature
  • Endothelium-derived relaxing factor (EDRF) is a labile humoral agent which mediates the action of some vasodilators. Nitrovasodi-lators, which may act by releasing nitric oxide (NO), mimic the effect of EDRF and it has recently been suggested by Furchgott1 that EDRF may be NO. We have examined this suggestion by studying the release of EDRF and NO from endothelial cells in culture. NO was determined as the chemiluminescent product of its reaction with ozone2. The biological activity of EDRF and… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    The cardiovascular morbidity and mortality is significantly higher in chronic kidney disease (CKD) patients, especially in dialysis patients, than in normal population. The increased… Expand
    ConditionsKidney Transplant Failure
    InterventionProcedure
    INTERVENTIONAL CLINICAL TRIAL
    Hypoxemia is a common complication after aortic surgery. As this complication has an adverse effect on the postoperative course of the patient, early treatment is important; however, the… Expand
    ConditionsAortic Surgery, Hypoxemia, Nitric Oxide
    InterventionDevice, Drug
    BLOG POST
    INTERVENTIONAL CLINICAL TRIAL
    Many studies have addressed the relationship between metabolic syndrome and cardiovascular disease. Risk factors include abdominal obesity, insulin resistance, abnormal lipid profile… Expand
    ConditionsMetabolic Syndrome
    InterventionDrug